Express News | Arvinas Appoints Randy Teel, Ph.d., as Chief Business Officer
Moomoo 24/7Apr 24 16:30 ET
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today a
ArvinasApr 24 00:00 ET
Analyst Forecasts For Arvinas, Inc. (NASDAQ:ARVN) Are Surging Higher
Arvinas, Inc. (NASDAQ:ARVN) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. The analysts greatly increased their rev
Simply Wall StApr 17 15:58 ET
Express News | HC Wainwright & Co. Maintains Buy on Arvinas, Lowers Price Target to $87
Moomoo 24/7Apr 15 07:28 ET
Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
Yahoo FinanceApr 12 13:55 ET
Piper Sandler Sticks to Their Buy Rating for Arvinas Holding Company (ARVN)
TipRanksApr 12 08:29 ET
Arvinas Is Maintained at Buy by HC Wainwright & Co.
Arvinas Is Maintained at Buy by HC Wainwright & Co.
Dow JonesApr 12 07:25 ET
Arvinas Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/12/2024 133.49% HC Wainwright & Co. $90 → $87 Maintains Buy 03/25/2024 74.45% Truist Securities → $65 R
BenzingaApr 12 07:14 ET
Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME), Arvinas Holding Company (ARVN) and Viridian Therapeutics (VRDN)
TipRanksApr 12 07:10 ET
Express News | Arvinas, Inc. : H.c. Wainwright Cuts Target Price to $87 From $90
Moomoo 24/7Apr 12 06:53 ET
Novartis (NVS.US) received Arvinas's potential “best-in-class” proteolytic agent for over $1 billion
Arvinas (ARVN.US) announced that it has reached an exclusive strategic licensing agreement with Novartis/NVS.us (Novartis/NVS.us).
Zhitong FinanceApr 11 21:37 ET
Buy Rating Affirmed for Arvinas Amid Strategic Novartis Deal and Growth Potential
TipRanksApr 11 13:05 ET
Fastenal, CarMax Fall; Alpine Immune Sciences, Arvinas Rise, Thursday, 4/11/2024
BarchartApr 11 12:25 ET
Express News | Arvinas Inc : Wedbush Cuts Target Price to $57 From $59
Moomoo 24/7Apr 11 10:49 ET
Express News | Arvinas Shares up 6.1% Co Enters Into Global License Agreement With Novartis for Prostate Cancer Drug
Moomoo 24/7Apr 11 09:33 ET
UPDATE 2-Novartis Taps Arvinas' Cancer Drug for up to $1 Billion
Yahoo FinanceApr 11 08:59 ET
Arvinas Agrees to License Prostate Cancer Treatment, Sell AR-V7 Program to Novartis
Arvinas (ARVN) said Thursday it has entered into agreements with Novartis (NVS) for the development and commercialization of its ARV-766 prostate cancer treatment and the sale of its AR-V7 preclinical program.
MT NewswiresApr 11 08:56 ET
Express News | Arvinas Shares Are Trading Higher After the Company Entered a License Agreement With Novartis for the Development and Commercialization of ARV-766 in Prostate Cancer Treatment
Moomoo 24/7Apr 11 07:25 ET
Arvinas Enters Exclusive Strategic License Agreement With Novartis; Arvinas To Receive $150M Upfront Payment & Up To $1.01B In Milestones
The deal is for the worldwide development and commercialization of ARV-766, Arvinas' second generation PROTAC androgen receptor (AR) degrader for patients with prostate cancer. The transaction also in
BenzingaApr 11 07:22 ET
Express News | Arvinas Shares up 3.5% Premarket After Novartis and Co Enter Into Global License Agreement for Prostate Cancer Drug
Moomoo 24/7Apr 11 07:11 ET
No Data
No Data